Daily Cosmetic Research Analysis
Three studies shape cosmetic and aesthetic medicine today: a Delphi consensus from cosmetic dermatologists clarifies which topical ingredients they recommend for common concerns; a bioprocess study scales rosmarinic acid production in Lavandula angustifolia to a 1-ton bioreactor with in vitro antimelanogenic and procollagen effects; and a prospective phase II analysis supports safe, cosmesis-preserving partial breast irradiation after oncoplastic surgery. Together they inform evidence-based skin
Summary
Three studies shape cosmetic and aesthetic medicine today: a Delphi consensus from cosmetic dermatologists clarifies which topical ingredients they recommend for common concerns; a bioprocess study scales rosmarinic acid production in Lavandula angustifolia to a 1-ton bioreactor with in vitro antimelanogenic and procollagen effects; and a prospective phase II analysis supports safe, cosmesis-preserving partial breast irradiation after oncoplastic surgery. Together they inform evidence-based skincare guidance, sustainable sourcing of bioactive cosmetic ingredients, and oncologic radiotherapy planning with aesthetic outcomes.
Research Themes
- Evidence-based cosmeceutical ingredient recommendations
- Sustainable bioproduction of botanical actives for cosmetics
- Oncoplastic breast surgery and cosmesis-preserving radiotherapy
Selected Articles
1. Elicitor-mediated enhancement of rosmarinic acid biosynthesis in cell suspension cultures of Lavandula angustifolia and in vitro biological activities of cell extracts.
Methyl jasmonate elicitation in Lavandula angustifolia cell suspensions boosted rosmarinic acid to 16.4 mg/g DW by upregulating pathway genes, and scale-up to a 1-ton bioreactor yielded extracts with strong antioxidant, antimelanogenic, and procollagen-stimulating activity in vitro. This demonstrates a feasible, industrially relevant pipeline for sustainable cosmetic actives.
Impact: It unites pathway-level control with industrial scale-up and functionally relevant in vitro readouts directly tied to cosmetic endpoints (pigmentation and dermal matrix).
Clinical Implications: While preclinical, RA-enriched L. angustifolia extracts with antimelanogenic and procollagen activity could inform dermatologists’ recommendations and formulators’ sourcing for hyperpigmentation and photoaging products; human safety and efficacy trials are needed.
Key Findings
- Methyl jasmonate (100 μM, 3 days) increased rosmarinic acid to 16.4 mg/g DW in cell suspensions.
- Elicitation upregulated RA-pathway genes (PAL, C4H, 4CL, TAT, HPPR, AAT1, CYP450).
- 1-ton bioreactor MJ-treated extracts showed high antioxidant activity, inhibited melanin synthesis, and enhanced procollagen synthesis in vitro.
- Demonstrated feasibility of large-scale culture for cosmetic/pharmaceutical applications.
Methodological Strengths
- Combined metabolic elicitation with gene expression profiling to link mechanism and yield.
- Demonstrated industrial-scale (1-ton) bioreactor feasibility with functional bioassays relevant to cosmetics.
Limitations
- Preclinical in vitro assays; no human efficacy or safety data.
- Batch-to-batch variability and long-term stability of cell cultures not fully characterized.
Future Directions: Conduct standardized safety and efficacy trials in humans (topical formulations), optimize downstream purification and stability, and compare RA-enriched extracts head-to-head with conventional sources.
Lavandula angustifolia is widely reported for its biological activities and essential compounds. However, research confirming the physiological activities of L. angustifolia cell suspension culture extracts is limited. In this study, a high-yield method utilizing elicitation techniques was developed, specifically aimed at enhancing the production of rosmarinic acid (RA) in L. angustifolia cell suspension cultures. Among the various elicitors tested, methyl jasmonate (MJ) treatment was the most effective in enhancing RA production. The highest RA production [16.4 mg/g dry weight (DW)] was observed in cell suspension cultures treated with 100 μM MJ for 3 days. MJ application activated the expression of structural genes (PAL, C4H, 4CL, TAT, HPPR, AAT1, and CYP450) involved in the RA biosynthetic pathway, thereby significantly enhancing RA production. Furthermore, extracts from MJ-treated cell cultures grown in a 1-ton bioreactor exhibited significantly high antioxidant activity, inhibition of melanin synthesis, and enhanced procollagen synthesis. These findings not only demonstrate the feasibility of large-scale cultures of MJ-treated L. angustifolia cells but also highlight their industrial potential for applications in cosmetics and pharmaceuticals.
2. Ultrahypofractionated partial breast irradiation following oncoplastic surgery: secondary analysis of a phase II trial.
In a prospective phase II cohort (50 patients, 52 tumors), ultrahypofractionated PBI after oncoplastic surgery achieved comparable dosimetry, excellent long-term aesthetic scores, and no local recurrences at a median 46 months when guided by MRI, seroma, and clips. The data support safe PBI use post-oncoplastic reconstruction in selected low-risk patients.
Impact: This addresses a frequent real-world scenario—PBI after oncoplastic rearrangement—providing prospective evidence for safety and aesthetics, informing multidisciplinary planning.
Clinical Implications: For low-risk early breast cancer with oncoplastic reconstruction, PBI (30 Gy in 5 fractions) can be considered when imaging and surgical markers allow confident target definition; counsel patients that cosmesis is maintained and may improve over time.
Key Findings
- Among 50 patients (52 tumors), 48% underwent oncoplastic reconstruction; no significant dosimetric differences vs standard lumpectomy (p > 0.05).
- Long-term BCTOS aesthetic scores converged between groups (>2 years: 1.29 vs 1.35; p = 0.71).
- No local recurrences at median 46 months follow-up.
- MRI, seroma, and surgical clips facilitated robust target delineation despite tissue rearrangement.
Methodological Strengths
- Prospective phase II design with standardized ultrahypofractionated regimen (30 Gy in 5 fractions).
- Use of MRI, clips, and seroma to guide target delineation; inclusion of patient-reported aesthetic outcomes (BCTOS) with long-term follow-up.
Limitations
- Single-arm secondary analysis with modest sample size; potential selection bias.
- Heterogeneity in oncoplastic techniques and target volume definitions may limit generalizability.
Future Directions: Randomized or matched comparative studies versus whole-breast irradiation and across oncoplastic techniques; incorporate cosmetic photography, objective fibrosis/edema metrics, and long-term oncologic endpoints.
PURPOSE: Although partial breast irradiation (PBI) is accepted as an effective and cosmesis-preserving technique for low-risk early-stage breast cancer following standard lumpectomy, data supporting PBI following oncoplastic surgery are sparse. We report prospective data in efforts to determine whether PBI can be safely utilized after oncoplastic surgery. METHODS: Patients with low-risk stage 0-1 breast cancer following successful lumpectomy with optional oncoplastic reconstruction were enrolled on a phase II trial. Patients were treated with a modified Florence regimen to 30 Gy in 5 fractions on the Varian Edge radiosurgery system using IMRT or VMAT. Presurgical MRI, post-operative seroma and surgical clips were used to assist target delineation. The effect of oncoplastic surgery on radiation dosimetry and Breast Cancer Treatment Outcome Scale scores were assessed using student's t-test for continuous variables and chi-square for categorical variables. RESULTS: From 2018 to 2022, 50 patients with 52 tumors were enrolled with 48% undergoing oncoplastic reconstruction. Although median PTV volumes were numerically larger in the oncoplastic group (266 cc vs. 223 cc), there were no statistically significant differences in PTV volumes, ratio of PTV to whole breast or mean heart or lung doses (p > 0.05). Mean baseline BCTOS aesthetic scores were 1.35 for standard lumpectomy vs. 2.52 for oncoplastic (p = 0.003). At long-term follow-up > 2 years, mean BCTOS aesthetic scores were 1.29 for standard lumpectomy vs. 1.35 for oncoplastic (p = 0.71). At a median follow-up of 46 months, there were no local recurrences. CONCLUSIONS: When utilizing pre-treatment MRI, surgical clips and a relatively large PTV, PBI after oncoplastic surgery was safe and effective for appropriately selected patients. In combination with oncoplastic surgery, partial breast irradiation achieves excellent long-term cosmesis that improves over time.
3. Skincare ingredients recommended by cosmetic dermatologists: A Delphi consensus study.
Using a two-round Delphi across 62 cosmetic dermatologists, consensus emerged on 23 topical ingredients for common concerns, with retinoids, niacinamide, azelaic acid, benzoyl peroxide, salicylic acid, glycolic acid, vitamin C, and mineral sunscreen among those endorsed—mostly supported by level 1b–2b evidence. This provides pragmatic, evidence-aligned guidance for skincare recommendations.
Impact: It standardizes expert practice in a high-demand area and maps consensus to evidence, likely shaping guidelines, patient counseling, and product development.
Clinical Implications: Clinicians can align skincare counseling with consensus-backed ingredients for specific concerns (e.g., retinoids for wrinkles/acne, niacinamide for redness/dark spots), while noting areas where evidence remains limited.
Key Findings
- From 318 candidate ingredients, experts narrowed to 83, then achieved consensus on 23 via two-round Delphi (62 dermatologists, 43 centers).
- Endorsed ingredients include retinoids (multiple indications), niacinamide, azelaic acid, benzoyl peroxide, salicylic acid, glycolic acid, vitamin C, and mineral sunscreen.
- Most consensus ingredients are supported by level 1b or 2b evidence in the literature.
Methodological Strengths
- Structured Delphi methodology across multiple centers with pre-specified literature-informed item generation.
- Explicit linkage of consensus items to supporting evidence levels.
Limitations
- Expert consensus remains partly opinion-based and may reflect regional practice patterns.
- Heterogeneity in product formulations and lack of head-to-head randomized trials for many ingredients.
Future Directions: Prioritize randomized, head-to-head clinical trials for leading ingredients and develop standardized outcome measures for cosmetic efficacy and tolerability.
BACKGROUND: There is ambiguity regarding the topical cosmetic ingredients preferred for common skin complaints. OBJECTIVE: To determine which topical ingredients are frequently recommended by cosmetic dermatologists for fine lines and wrinkles, acne, redness, dark spots, large pores, dry skin, and oily skin. METHODS: Literature review to develop long list of ingredients. Reduced by expert panel to most salient ingredients. Two rounds of Delphi consensus survey with second expert panel of clinicians and teachers. Comparative literature review to summarize published evidence supporting each consensus ingredient. RESULTS: List of 318 ingredients reduced by a panel of 17 dermatologists to 83. Two Delphi rounds completed by 62 dermatologists at 43 centers. Consensus achieved for 23 ingredients, including the following: azelaic acid (acne, dark spots); benzoyl peroxide (acne, oily skin); glycolic acid (acne, dark spots); mineral sunscreen (fine lines and wrinkles, redness); niacinamide (redness, dark spots); retinoids (fine lines and wrinkles, acne, dark spots, large pores, oily skin); salicylic acid (acne, oily skin); vitamin C (fine lines and wrinkles, dark spots). Most consensus ingredients supported by level 1b or 2b evidence. LIMITATIONS: Some ingredients based on expert opinion. CONCLUSION: Consensus exists among expert cosmetic dermatologists regarding ingredients most useful for common dermatologic concerns.